Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMBD-002 with or without pembrolizumab in advanced solid tumors
NCT05082610Phase 1Completed
- Sponsor
- Hummingbird Bioscience
- Start
- Feb 2022
- Primary completion
- Nov 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of HMBD-002 in cancer (4 arms), sponsored by Hummingbird Bioscience. Primary endpoints: Dose-limiting Toxicity at 21 days, Dose-Finding and 1 more. Started Feb 2022; status: completed.
02
Drugs
HMBD-002
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05082610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05082610.